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Although in the last decades the molecular underpin-
nings of the cell cycle have been unraveled, the acquired 
knowledge has been rarely translated into practical 
applications. Here, we investigate the feasibility and 
safety of triggering proliferation in vivo by temporary 
suppression of the cyclin-dependent kinase inhibitor, 
p21. Adeno-associated virus (AAV)-mediated, acute 
knockdown of p21 in intact skeletal muscles elicited 
proliferation of multiple, otherwise quiescent cell types, 
notably including satellite cells. Compared with con-
trols, p21-suppressed muscles exhibited a striking two- 
to threefold expansion in cellularity and increased fiber 
numbers by 10 days post-transduction, with no detect-
able inflammation. These changes partially persisted for 
at least 60 days, indicating that the muscles had under-
gone lasting modifications. Furthermore, morphological 
hyperplasia was accompanied by 20% increases in maxi-
mum strength and resistance to fatigue. To assess the 
safety of transiently suppressing p21, cells subjected to 
p21 knockdown in vitro were analyzed for γ-H2AX accu-
mulation, DNA fragmentation, cytogenetic abnormali-
ties, ploidy, and mutations. Moreover, the differentiation 
competence of p21-suppressed myoblasts was investi-
gated. These assays confirmed that transient suppression 
of p21 causes no genetic damage and does not impair 
differentiation. Our results establish the basis for further 
exploring the manipulation of the cell cycle as a strategy 
in regenerative medicine.
Received 9 June 2014; accepted 3 February 2015; advance online  
publication 10 March 2015. doi:10.1038/mt.2015.27
INTRODUCTION
Regenerative medicine encompasses a variety of currently avail-
able or envisioned therapeutic approaches ranging from cell 
replacement therapy to in vivo tissue or organ regeneration.1 
Despite their largely solid biological bases, many such approaches 
are marred by practical hurdles, one of which is insufficient cell 
proliferation. Slow proliferation hampers cultivation of a variety 
of therapeutically relevant cell types, e.g., human-derived stem 
cells.2 Equally affected is regeneration of many diverse tissues 
in vivo. By way of example, cartilage, tendon, and bone require 
extensive periods of time to heal, often imperfectly.3 There clearly 
is a widespread need for techniques to induce or accelerate cell 
proliferation.
The central cell cycle regulatory molecules,  cyclin-dependent 
kinases (CDKs), are activated by the binding of cyclins and 
restricted by CDK inhibitors (CDKIs). CDKIs belong to either 
the INK4 or the Cip/Kip family.4 The first group includes four 
CDKIs that selectively bind Cdk4 and Cdk6 and prevent their 
association with D-type cyclins. The Cip/Kip family is comprised 
of three members, p21 or CDKN1A, p27 or CDKN1B, and p57 
or CDKN1C, which preferentially bind cyclin/Cdk complexes and 
have broad inhibitory abilities.5 CDKIs are expressed at high levels 
in most types of nonproliferating cells and critically contribute to 
preserve cell cycle dormancy.6
We have previously found that cells can be brought back into 
the cell cycle from all nonproliferation states, including termi-
nal differentiation and senescence as well as quiescence, by sim-
ply removing appropriate cell cycle inhibitors, most importantly 
p21.6 Such remarkable effect is mediated by preassembled cyclin/
Cdk/CDKI complexes that spontaneously acquire activity upon 
removal of the inhibitory molecule.6,7 Terminally differentiated 
cells, though reentering the cell cycle, generally cannot be made 
to proliferate.8–14 In contrast, quiescent cells readily multiply fol-
lowing CDKI removal, even in the absence of exogenous growth 
factors.6
In this article, we explore CDKI suppression as a means to 
activate or expedite the proliferation of quiescent cells in vivo 
and promote or accelerate tissue repair. We show that acute p21 
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removal in vivo triggers different cell types to proliferate, includ-
ing satellite cells, greatly but temporarily increasing the cellular-
ity of skeletal muscle and causing striking increases in strength 
and endurance. Furthermore, we show that transient p21 removal 
causes no harm to the cells. In particular, it does not induce apo-
ptosis, DNA damage, chromosomal aberrations, or mutations and 
does not affect the skeletal muscle differentiation program. Thus, 
at least in principle, a variety of regenerative medicine approaches 
might benefit from controlled CDKI removal.
RESULTS
p21 suppression elicits cell proliferation in vivo
Although we had previously shown that interference with p21 
forcefully stimulates proliferation of cultured cells, the question 
remained whether it could attain similar effects in vivo. To address 
this point, we electroporated otherwise intact mouse tibialis 
anterior (TA) muscles with p21 or control siRNA. As early as 3 
days after electroporation, large areas of the p21 siRNA-transduced 
muscle displayed greatly increased cellularity (Supplementary 
Figure S1). In principle, these results showed that p21 suppres-
sion is as effective in vivo as in vitro in triggering proliferation 
of quiescent cells. However, the induced hypercellular areas were 
patchy, presumably due to inhomogeneous siRNA transduction, 
and tissue damage from electroporation complicated the interpre-
tation of the results.
AAV-mediated p21 siRNA elicits strong and uniform 
proliferation of multiple cell types
To overcome the limitations of electroporation, we explored 
the possibility of using adeno-associated virus (AAV) vectors 
to transduce the muscle tissue in a more uniform and less inva-
sive fashion. To this end, we injected a LacZ-carrying, serotype 
Figure 1  Effects of adeno-associated virus (AAV9)-mediated suppression of p21 in the skeletal muscle. (a) β-Gal expression in the right tibialis 
anterior (TA) muscle infected with AAV9-LacZ. In the same mouse, the contralateral muscle was injected with the control virus (AAV9-Ctr). The muscles 
were harvested 10 days postinfection and stained for β-Gal. (b) Time course analysis of p21 mRNA levels in TA muscles. Mice received intramuscular 
injections of AAV9-p21 or AAV9-Ctr and the muscles were harvested at 3, 6, 9, 12, 15, and 20 days postinfection. qPCR-measured p21 mRNA levels are 
shown as percentages of those of AAV9-Ctr-injected muscles. Values are the averages of two experiments. (c) Total nuclei and (d) BrdU incorporation 
in AAV9-p21 infected TA muscles 10 days postinjection. The right and left TA muscles of 3 mice were infected with the indicated viruses. Sections were 
stained with Hoechst 33258 (blue) and subjected to immunofluorescence for laminin (red) and BrdU (green). (e) Leukoocytes in AAV9-p21 infected 
muscles. TA muscles were infected with AAV9-p21, AAV9-Ctr, or with a replication-impaired mutant adenovirus serotype 5 (dl520). The muscles were 
fixed 10 days postinfection and stained with an antibody to CD45. Nuclei were counterstained with Hematoxylin. Bar: 50 μm.
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9  AAV (AAV9-LacZ) vector into the TA muscles of C57BL/6 
mice. In two independent experiments, 10 days postinjection, 83 
and 100% of the fibers, respectively, showed intense β-gal expres-
sion throughout the length of the muscles (Figure 1a). This result 
prompted us to construct an AAV9 vector carrying four copies 
of a p21 shRNA under the control of the H1 PolIII promoter 
(AAV9-p21). TA muscles were injected with this vector or its 
control (AAV9-Ctr) and harvested 3–20 days after injection. To 
label DNA-replicating cells, some of the mice were administered 
5-bromo-2′-deoxyuridine (BrdU) in drinking water for variable 
periods of time before sacrifice.
Effective suppression of p21 was demonstrated by quantita-
tive polymerase chain reaction (qPCR). Figure 1b shows that, 6 
days after injection, p21 mRNA was reduced more than 10-fold 
in AAV9-p21-infected muscles, compared with control muscles. 
A fourfold reduction persisted for at least 20 days postinjection.
Histological examination showed a progressive increase in the 
number of nuclei in the AAV9-p21-infected muscles, compared 
with AAV9-Ctr-injected or mock-treated controls. The increase 
became first appreciable at day 5 after injection and peaked at 
day 10, when the number of nuclei per tissue section, in differ-
ent experiments, was two- to threefold larger in p21-suppressed 
muscles, compared with control ones (Figure  1c). Other mor-
phological features of p21-knockdown (KD) muscles will be 
described later (see further below, Figure 4 and Supplementary 
Figures S4 and  S5). BrdU immunofluorescence showed that 
a large proportion of the nuclei in p21-suppressed muscles had 
undergone DNA replication (Figure  1d), indicating that the 
increased cellularity observed was due to proliferation, rather 
than migration of exogenous (e.g., inflammatory) cells. To directly 
exclude that AAV injection and/or interference with p21 might 
cause inflammation, muscle sections were stained with a pan-
leukocyte, anti-CD45 antibody, which detected white blood cells 
neither in control nor in p21-suppressed muscles (Figure 1e), con-
sistent with the notion that AAV efficiently infects skeletal muscle 
with virtually no inflammatory response.15 A replication-impaired 
mutant of adenovirus serotype 5, known to cause a strong inflam-
matory response, was used as a positive control.
To determine which cell types are induced to proliferate by 
p21 suppression, tissue sections were stained, 10 days postinfec-
tion, with histotype-specific antibodies (Figure 2; quantitation in 
Supplementary Table S1). Staining for the Pax7 transcription fac-
tor showed that satellite cells were increased more than threefold 
in p21-suppressed vs. control muscles (Figure 2a). Similarly, the 
number of CD31-positive (CD31+), endothelial cells was 1.5-fold 
higher in p21-KD muscles (Figure 2b). In addition, staining with 
a connective tissue-specific monoclonal antibody16 (BM4018, 
see Materials and Methods) showed this compartment to be 
expanded in p21-KD muscles (Figure 2c), suggestive of increased 
mesenchymal cell numbers.
Importantly, 39% of Pax7+ cells were labeled by BrdU in 
p21-suppressed muscles, compared with 6% in controls (Figure 2d 
Figure 2 Analysis of cell subpopulations in adeno-associated virus (AAV)9-p21-infected tibialis anterior (TA) muscles. TA muscles infected as 
in Figure 1c,d were stained for the indicated antigens 10 days postinfection. Pax7+ cells were counted in entire sections from each AAV9-p21- or 
– Ctr-infected muscle (data in Supplementary Table S1). All sections were also stained with Hoechst 33258 (blue). Bar: 40 μm.
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and Supplementary Table S1), further demonstrating satellite cell 
proliferation.
To explore this relevant issue more in depth, we infected 
TA muscles of transgenic mice expressing NLS-LacZ under the 
control of a partial desmin promoter (des/NLS-LacZ). Though 
expressed at moderate levels in myofibers, desmin is strongly 
upregulated in proliferating satellite cells (SC). The des/NLS-LacZ 
mice display detectable β-gal activity only in the nuclei of the lat-
ter, presumably due to the incompleteness of the desmin promoter 
in the transgene.17,18 These experiments showed a 10-fold increase 
in the number of activated SC, in AAV9-p21- versus -Ctr-infected 
muscles (Supplementary Figure S2) at day 10 postinfection. The 
apparent discrepancy between this large increase and the smaller 
one detected by direct Pax7 staining is attributable to the fact that 
Pax7 is downregulated upon muscle differentiation. In contrast, in 
des/NLS-LacZ mice, persistence of the β-Gal protein allows visu-
alization of SC that has fused with muscle fibers (Supplementary 
Figure S2).
Altogether, these results confirm6 that p21 KD is capable of 
eliciting proliferation in a broad range of cells.
p21 knockdown induces satellite cell proliferation
In view of potential applications of p21 KD in regenerative medi-
cine, it was important to ascertain that satellite cells can be directly 
reactivated by p21 suppression. To this aim, we investigated 
whether Pax7+ satellite cells can be efficiently infected by AAV9, as 
suggested by Dey et al.19 Intact fibers were isolated from TA mus-
cles 8 days after injection with AAV9-LacZ and put in culture. Two 
days later, cells migrated away from the fibers were doubly stained 
for β-galactosidase and Pax7 (Figure  3 and Supplementary 
Figure S3). Of the Pax7+ cells, 83.1% were β-galactosidase+, show-
ing that satellite cells are infected by AAV9 with an efficiency 
approaching that of muscle fibers (83–100%, see above). Together 
with the ability of in vivo p21 KD to expand Pax7+ cells, induce 
them to incorporate BrdU, and trigger cell cycle reentry in a range 
of different cells,6 these results strongly indicate that satellite cell 
proliferation can be induced in vivo by suppression of p21.
Short- and long-term morphological effects of p21 
suppression in skeletal muscle
To assess the short- and long-term consequences of cell cycle reac-
tivation, TA muscles were injected with AAV9-p21 or -Ctr vector 
and harvested 10, 20, 40, and 60 days thereafter. Sections repre-
sentative of the entire lengths of AAV9-p21-infected muscles and 
controls were stained with hematoxylin and eosin (Figure 4a). In 
p21-suppressed muscles, on day 10 from injection, tissue archi-
tecture appeared somewhat disorganized. As already described, 
these muscles displayed diffuse hypercellularity with further, focal 
increases. Fiber density was augmented and fiber cross-sectional 
area reduced. With time and to various degrees depending on the 
experiment, p21-suppressed muscles tended to revert to a more 
normal structure (Figure 4a). However, a number of morphologic 
changes were retained, at least in part, up to 60 days postinfection, 
the last time point examined.
Morphometric evaluation of tissue sections showed (Figure 4b 
and Supplementary Figure S4) that the total number of nuclei 
per section remained greater, in p21-KD versus control muscles, 
from day 10 to 60. Similarly, the number of fibers was persistently 
increased by about 15% throughout the experiment, indicating 
that p21 suppression results in fiber neoformation. Such increase 
was balanced in part by a reduced fiber cross-sectional area 
(average, 80% of control fibers, Figure  4b and Supplementary 
Figure S4). However, p21-KD whole-muscle cross-sectional areas 
remained enlarged (from 108% at day 10 to 103% at day 60, com-
pared with controls muscles; data not shown). While 51.9% of 
the p21-KD fibers displayed central nuclei at day 10, by day 60 
the nuclei were mostly peripheral (p21-KD, 10.4% centronucle-
ated fibers; control, 3.9%). This suggests that p21 suppression did 
not affect the maturation of the centronucleated fibers, of which 
nucleus peripheralization represents a morphological hallmark.17 
Trichrome staining showed that initially p21 suppression caused 
moderate fibrosis (blue-colored), which progressively disappeared 
over the next 50 days (Supplementary Figure S5).
p21 suppression in skeletal muscle induces transient 
increases in strength and endurance
We wished to evaluate whether the morphological remodeling 
brought about by p21 suppression is accompanied by functional 
Figure 3 In vivo satellite cell infection with adeno-associated virus 
(AAV)9-LacZ. The tibialis anterior (TA) muscles of 3 mice were infected 
with AAV9-LacZ and were harvested 8 days postinfection. Fibers were iso-
lated and cultured as described.29 After 3 days in culture, cells detached 
from the fibers were stained for Pax7 (red) and β-Gal (green). Also 
shown, phase contrast pictures of the same fields. The pictures in the 
upper panels display double-positive cells. Staining specificity is shown 
in the middle and bottom panels, depicting cells positive for either Pax7 
or β-Gal alone. Further examples are shown in Supplementary Figure 
S3. Bar: 40 μm.
Phase contrast Pax7 β-Gal
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changes. To this aim, extensor digitorum longus (EDL) muscles 
were subjected to functional measurements 20 and 60 days after 
AAV9-p21 or AAV9-Ctr infection.
At day 20 after infection with AAV9-p21, the EDL muscles 
showed an average 12% increase in total weight, compared with 
AAV9-Ctr-infected muscles (P  <  0.05), in keeping with their 
hyperplastic features. Strikingly, p21-KD muscles exhibited an 
average 20% increase in maximum force (P  <  0.05, Figure  4c). 
The maximum specific force was also augmented in AAV9-p21-
infected muscles, although the difference did not reach statistical 
significance. Furthermore, p21-KD EDLs showed a 21% increase 
in resistance to isotonic fatigue (P < 0.05, Figure 4c).
Figure 4 Effects of cell cycle reactivation in adeno-associated virus (AAV)9-p21-infected muscles. Three C57Bl/6 mice per experimental point 
were injected in both the right and left TA with AAV9-p21 or with AAV9-Ctr. (a) Sections were stained with hematoxylin and eosin at 10, 20, 40, 
and 60 days postinjection (p.i.). (b) Number of nuclei and fibers per surface unit and average fiber cross-sectional area. Sections from three different 
mice were scored at each time point. The results in p21-KD muscles are presented as percentages of controls. Confidence intervals for these data are 
shown in Supplementary Figure S4. (c) Mean ± SEM of maximum force (upper panels), specific force (middle panels) and time to fatigue (lower 
panels) of extensor digitorum longus muscles infected with the indicated viruses. Day 20: AAV9-p21, n = 4; -Ctr, n = 6. Day 60: -p21, n = 6; -Ctr, 
n = 5. Bar: 40 μm.
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Sixty days after infection, the residual weight (6%, not shown) 
and functional differences in favor of AAV9-p21-infected muscles 
were no longer statistically significant.
These results show that the morphological changes gener-
ated by p21 suppression are closely paralleled by improvements 
in strength and endurance, indicating that the additional fibers 
generated as a result of cell proliferation are fully functional.
Temporary p21 suppression causes no detectable 
genetic or cytogenetic alterations
p21 is a major player in the DNA damage response, its main role 
being that of temporarily arresting damaged cells to allow repair 
or permanently sequestering irredeemable cells in senescence.20 
A strategy devised for regenerative medicine applications cannot 
afford damaging cells; thus, we subjected p21 KD cells to a variety 
of tests to ascertain their integrity.
To assess whether p21 suppression causes DNA breaks or 
allows them to accumulate unrepaired, serum-starved, quies-
cent human fibroblasts were reactivated by either addition of 
serum in the culture medium or p21 RNA interference (RNAi). 
Figure 5a shows that neither treatment caused accumulation of 
serine 139-phosphorylated histone H2AX (γ-H2AX), a marker 
of DNA double-strand (ds) breaks.21 Fibroblasts were selected 
because they can be readily made quiescent by serum starva-
tion, whereas mouse myoblasts would differentiate in the absence 
of growth factors. However, similar results were obtained with 
human myoblasts (Supplementary Figure S6), whose longer dif-
ferentiation time allows to operationally separate quiescence from 
differentiation.
The possibility that p21 KD induces DNA ds breaks was also 
investigated using an alkaline comet assay, that directly visual-
izes both single-strand and ds breaks. Consistent with the lack of 
γ-H2AX accumulation, serum-starved human fibroblasts, reacti-
vated by serum administration or p21 RNAi, showed no more DNA 
fragmentation than proliferating or quiescent cells (Figure 5b).
The potential for p21 KD to induce chromosomal aberrations 
or allow them to escape repair was investigated by cytogenetic anal-
ysis. Metaphases were prepared from proliferating normal human 
fibroblasts, transfected or not with p21 siRNA. The same cells, ren-
dered quiescent by serum starvation, were reactivated by serum 
addition or p21 RNAi and subjected to cytogenetic analysis at the 
time of their first mitosis. The types and numbers of chromosomal 
aberrations detected in all of these conditions showed no significant 
differences (Table 1). The number of aneuploid cells also showed 
no meaningful changes in any of the settings investigated (Table 1).
To determine whether p21 ablation negatively affects cells in 
the longer term, quiescent fibroblasts were transfected with p21 
or control siRNA and kept in culture in 0.1% fetal bovine serum 
(FBS) for nine days. While p21 KD cells proliferated in these con-
ditions, control siRNA-transfected cells were reactivated by serum 
addition 24 hours before harvesting for metaphase preparation. 
Again, no significant differences were observed between p21 KD 
and control fibroblasts, with regard to chromosomal aberrations 
and ploidy (Table 1, long term).
Finally, the possibility that p21 KD allowed mutations to accu-
mulate was investigated using the highly sensitive HPRT muta-
tion assay, which measures the frequency of acquired resistance to 
6-thioguanine (6-TG) in a cell population. Such resistance arises 
when the single functional copy of the HPRT gene on the active X 
chromosome acquires an inactivating mutation.
Quiescent human fibroblasts were reactivated by p21 RNAi 
or transfected with control siRNA. After four days in culture in 
the absence of serum, the cells were switched to serum-containing 
medium for further 5 days, then seeded in selective medium. In 
two independent experiments, the p21 KD cells showed a fre-
quency of 6-TG-resistant clones indistinguishable from that of 
controls. UV-treated, positive-control cells showed the expected 
high number of mutants (Table 2).
Altogether, these experiments show that medium-term sup-
pression of p21 is well tolerated by cells and does not cause DNA 
damage, chromosomal aberrations, or genetic mutations.
Figure 5 Assessment of DNA damage in p21-suppressed human 
fibroblasts. Normal, primary, human fibroblasts were rendered quies-
cent (Q) by culturing them in medium containing 0.1% fetal bovine 
serum for 96 hours. They were then subjected to RNAi for GFP (Q+siGFP, 
control) or p21 (Q+sip21). Proliferating cells (Prol) were added as a ref-
erence; quiescent cells treated with phleomycin (Q+phleo, 50 μg/ml 
for 5 hours) were included as a positive control for DNA damage. (a) 
Cells were harvested 48 hours post-treatment and analyzed by western 
blotting for the indicated proteins. (b) Cells were harvested 48 hours 
post-treatment and analyzed by comet assay. The graph shows average 
tail moment ± standard deviation; bottom pictures show examples of 
the analyzed nuclei. At least 65 nuclei per experimental condition were 
analyzed.
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p21 suppression does not impair the skeletal muscle 
differentiation program
To determine whether p21 KD might affect muscle differentia-
tion, primary mouse myoblasts were transfected with control or 
p21 siRNA and induced to differentiate from 2 to 10 days after 
transfection. Western blotting showed that p21 was suppressed in 
myoblasts until 4 days from transfection (Figure 6a). No reduc-
tion was found in the ability of p21-suppressed cells to differen-
tiate or fuse at any time point (Figure 6b,c and Supplementary 
Figure S7). Thus, contrary to what has been reported for consti-
tutive, p21 KO mice,22 acute ablation of p21 does not apprecia-
bly affect skeletal muscle differentiation in vitro. Indeed, in vivo, 
p21 KD-reactivated satellite cells ostensibly fuse with preexisting 
myofibers or form new ones (centronucleated fibers, Figure  4), 
reinforcing the conclusion that full p21 expression is not indis-
pensable for skeletal muscle differentiation.
DISCUSSION
In this paper, we address two critical issues concerning the manip-
ulation of the cell cycle in favor of regenerative medicine: efficacy 
and safety. We show that acute p21 ablation in the context of intact 
skeletal muscle tissue triggers multiple cell types to undergo a brief 
but intense proliferation burst. Furthermore, a variety of assays 
carried out with multiple cell types detected no genetic, chromo-
somal, or differentiative alterations as results of p21 suppression.
In analyzing what cell types are induced to proliferate by p21 
KD, we focused our attention on satellite cells, because of their 
therapeutic significance. We show that these cells are efficiently 
infected by AAV9 and, in response to p21 suppression, incorpo-
rate BrdU in vivo and dramatically increase in number. Recently, 
it has been shown that skeletal muscle precursor cells include a 
slowly-proliferating, label-retaining, self-renewing subpopulation 
and a differentiation-committed one.23 Proliferation of the latter 
subpopulation appears to be controlled by p21, while the former 
is largely p21-independent. On the basis of these results, cell cycle 
reactivation mediated by p21 KD should act mostly or exclusively 
on the more committed progenitor cells. Although the precise tar-
get of p21 KD is relevant to design long-term therapeutic strat-
egies, in the present work we have not directly investigated this 
issue.
The hyperproliferation brought about by p21 KD spontane-
ously ceases within 15–20 days, though p21 mRNA remains 
strongly downregulated until at least 20 days postinfection 
(Figure  1b). The finding that, in p21-KD muscles, fibers are 
increased in number but display a smaller average cross-sectional 
area (Figure  4) might suggest that suppression of the CDKI 
induces proliferation without concomitant, sufficient protein 
synthesis. Alternatively or in addition, homeostatic mechanisms 
at levels above that of cell cycle control might tend to bring the 
muscle back to its original state, in the absence of requests (e.g., 
overload or sustained exercise) for higher performance. In this 
view, such mechanisms would impinge on both trophism and pro-
liferation. At this stage, we have no data as to the molecular bases 
of the spontaneous return to quiescence.
Whatever the reasons for the transience of proliferation, it 
results in increased absolute fiber numbers (Figure 4b), leading 
to the remarkable conclusion that at least a fraction of the addi-
tional cells produced by p21 KD generate entirely new fibers. 
Furthermore, despite the short duration of proliferation, most 
tissue changes induced by the initial burst of cell division are 
long-lasting. Indeed, even 60 days after p21-KD, the total number 
of nuclei remained increased by 67% and that of fibers by 21% 
(Figure 4b).
The current results cannot distinguish whether muscle hyper-
plasia is solely the effect of p21 KD on satellite cells or, rather, 
proliferation of interstitial cells contributes to it, perhaps by 
modifying satellite cell behavior. This point will be investigated by 
driving p21 KD with cell type-specific promoters. Irrespectively, 
the hyperplasia induced by p21 suppression results in striking 
increases in both maximum strength and resistance to fatigue. The 
former is a clear indication of the functionality of the supernumer-
ary fibers induced by p21 KD. The latter is measured with a load 
equal to one third of maximum force, which allows each muscle to 
generate its maximum power. Thus, the stronger p21-KD muscles 
Table 1 Cytogenetic aberrations in human fibroblasts subjected to p21 RNAi
Initial  
proliferation state Treatment
Percent 
aneuploid
Chromosomes 
(average ± SD)
Total 
aberrations/cell
Gaps/ 
cell
Breaks/ 
cell
Proliferating — 4 45.99 ± 0.26 0.05 0.05 0
Proliferating p21 RNAi 8 45.98 ± 0.37 0.08 0.08 0
Quiescent p21 RNAi 2 45.99 ± 0.24 0.03 0.02 0.01
Quiescent Fetal bovine serum 4 46.00 ± 0.20 0.03 0.02 0.01
Quiescent Long-term p21 RNAi 6 45.97 ± 0.30 0.09 0.06 0.03
Quiescent Long-term Ctr RNAi 7 45.98 ± 0.42 0.08 0.06 0.02
SD, standard deviation.
Table 2 Mutation frequencies in p21-suppressed and control 
fibroblasts
Treatment
Mutation frequency (× 106)
Experiment 1 Experiment 2
Untreated ND 2.6
Ctr siRNA 7.4 3.5
p21 siRNA 7.0 3.3
UV 58.0 ND
Ctr siRNA + UV ND 50.6
p21 siRNA + UV ND 26.0
Ctr, control; ND, not done; UV, ultraviolet light (positive control).
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showed reduced fatigability even while undergoing a heavier exer-
tion than controls. This result implies an ameliorated capacity of 
the muscle to counteract fatigue, suggesting an increased energy 
reserve.
It will be of great interest to determine whether the hyper-
plastic response to p21 suppression can be converted into fiber 
hypertrophy, e.g., by subjecting p21-KD muscles to overload. Even 
more important, future studies will try to exploit induced hyper-
plasia for therapeutic purposes. However, downregulation of p21, 
as performed in this work, is unselective, being driven by the H1 
promoter. Generalized cell proliferation and deep tissue remod-
eling prevent a precise assessment of the benefits of p21 KD to 
muscle regeneration. Therapeutic approaches will need to focus 
on one or more specific cell types, particularly satellite cells.
Thus, the present results do not attempt to establish a thera-
peutic technique. Rather, they demonstrate in principle that pro-
liferation can be effectively and safely elicited, in vivo as well as 
in vitro, by manipulating a single CDKI. Hence, we predict that 
this approach will be of great value in accelerating the healing of a 
variety of focal or diffuse lesions from diseases or traumas, espe-
cially in slowly self-renewing/regenerating tissues.
Using a wide range of complementary assays, we have shown 
that, in vitro, transient downregulation of p21 causes no harm to 
cells. Temporary modulation should be precisely the objective of 
future therapeutic protocols. Indeed, in regenerative medicine, 
any induced or accelerated proliferation is required only for a 
limited period of time. To avoid interference from muscle dif-
ferentiation, most safety experiments have been performed with 
fibroblasts, rather than muscle cells. However, since the role of p21 
in cell cycle control and DNA repair is not believed to be tissue 
specific, our results should apply to most or all histotypes. In fact, 
they pertain equally to in vitro and in vivo applications of p21 KD 
and authorize designing and experimenting with such strategies.
The ability of p21 KD to trigger strong proliferation is in appar-
ent contrast with the largely normal phenotype of p21 knockout 
mice. However, it is well known that constitutive gene suppres-
sion in the course of development can often elicit compensatory 
responses,24 which are less likely or less prompt in the case of acute 
ablations (e.g., Camarda et al.25).
The finding that p21 suppression does not hinder myoblast 
differentiation is somewhat surprising, in light of previous results 
showing impaired differentiation of myogenic precursor cells and 
delayed regeneration of skeletal muscle in p21 knockout mice.22 
Once again, constitutive suppression22 and short-term interfer-
ence (this work) might produce different phenotypes. In any case, 
as already discussed, therapeutic, in vivo p21 suppression should 
Figure 6 Effects of p21 suppression on the skeletal muscle differentiation program. Proliferating SC were transfected with siRNA to p21 or control 
siRNA or mock transfected. Replica cultures were induced to differentiate as indicated, from 2 to 10 days post-transfection. The cultures were fixed 
three days later, stained for muscle-specific myosin heavy chain (MyHC, a marker of differentiation), counterstained with Hoechst 33258, and scored. 
(a) Western blot analyses of the indicated proteins. (b) Differentiation index (percentage of nuclei in MyHC+ cells) ± standard deviation. (c) Fusion 
index (percentage of nuclei in MyHC-positive cells with three or more nuclei) ± standard deviation. Micrographs are shown in Supplementary 
Figure S7.
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be strictly limited in time. Even if temporary p21 reduction led 
to a momentary impairment of muscle regeneration, the ampli-
fied population of satellite cells should promptly return to normal 
functionality and quicken the pace of tissue repair.
MATERIALS AND METHODS
Animals, in vivo electroporation, and adeno-associated vectors. Animal 
care followed the directives of the EU (86/609/EEC). The experimental pro-
tocol was approved by the National Committee of the Italian Ministry of 
Health. Wild type C57Bl/6 mice were purchased from Harlan (Indianapolis, 
IN). TA muscles of C57Bl/6 mice were electroporated as described26 with 
a siRNA to murine p21.6 Recombinant adeno-associated viruses serotype 
9 (AAV9) were produced in the laboratory of L. Zentilin and M. Giacca at 
the International Centre for Genetic Engineering and Biotechnology, Tri-
este, Italy and in the laboratory of A. Auricchio at the Telethon Institute of 
Genetics and Medicine, Naples, Italy. AAV9-p21 was constructed by insert-
ing 4 copies of a shRNA to murine p21 into an AAV backbone, as previously 
described.27 The antisense sequence for the shRNA to p21 is: 5′-AGCTTTT 
CCAAAAAGGTGATGTCCGACCTGTTCTCTCTTGAAGAACA 
GGTCGGACATCACCGGG-3′. The insertless AAV backbone was used as 
control. In some experiments, a different AAV9 vector was used, carrying 
a single copy of the p21 shRNA and constructed as described.28 In these 
experiments, the matching control was a virus containing an shRNA to an 
irrelevant mRNA (rhodopsin, only expressed in retinal photoreceptors).28 
No functional differences were observed between the two sets of viruses.
For intramuscular injections, mice were anesthetized with Avertin. 
All infections were performed with a single injection of 50 µl of a 1.5 × 1011 
vg/ml viral stock directly into the TA muscle, using a 32G needle. Satellite 
cell isolation from cultured fibers of AAV-LacZ infected muscles was 
performed as described.29
Immunofluorescence, histological analysis, and microscopy. For immu-
nofluorescence procedures, cells were fixed with 4% formaldehyde for 10 
minutes and permeabilized with 0.1% Triton X-100 (ICN Biomedicals, 
Aurora, OH) in  phosphate-buffered saline. Monoclonal antibodies 
(MoAbs) to the following antigens were used: BrdU (Bu20a clone, Dako-
Cytomation, Glostrup, Denmark); myosin heavy chain (MF20, ref. 30); 
γ-H2AX (05-636, Millipore (Billerica, MA)). Alexa Fluor 488- or 594-con-
jugated antisera to mouse immunoglobulins were obtained from Life 
Technologies (Carlsbad, CA). Nuclei were counterstained with Hoechst 
33258 (Sigma, St. Louis, MO).
For histological stainings, TA muscles were harvested and 
immediately snap frozen. Eight-micrometer cryosections were 
fixed in 4% paraformaldehyde and processed for histological and 
immunofluorescence analysis. The following MoAbs and antisera (AS) 
were used: sheep AS to BrdU (Ab1893, Abcam, Cambridge, UK); MoAb 
to Pax7 (Developmental Studies Hybridoma Bank, Iowa City, IA); rabbit 
AS to laminin (L9393, Sigma); rabbit AS to CD31 (Ab28364, Abcam); rat 
MoAb to reticular fibroblasts (Pan Reticular, BM4018, Acris Antibodies, 
Herford, Germany). Muscle sections were also stained with hematoxylin, 
eosin, and Masson’s trichrome (Sigma). Immunohistochemistry for CD45 
(rat AS 553082 Becton Dickinson, Franklin Lakes, NJ) was carried out on 
formalin-fixed sections, according to previously published procedures.31 
For double Pax7/BrdU staining, the following primary antibodies were 
used: MoAb to Pax7 (sc81648, Santa Cruz, Dallas, TX); biotinylated sheep 
AS to BrdU (ab2284, Abcam). All histological evaluations were carried 
out on transverse sections evenly distributed throughout the length of the 
muscle, to avoid biases due to local inhomogeneities.
Pictures were obtained using a fluorescence microscope (Axioskop 
2; Carl Zeiss MicroImaging, Oberkochen, Germany), with a 20× or 40× 
objective. Images were digitized with a camera (AxioCam; Carl Zeiss 
MicroImaging) and acquired with AxioVision 3.1 software (Carl Zeiss 
MicroImaging). Double Pax7/BrdU images were acquired using a Leica 
SPE confocal microscope with a 40× objective (Leica, Solms, Germany). 
Photographs were contrast enhanced by applying the brightness/contrast 
regulation of the Photoshop CS 8.0 software (Macintosh version, Adobe, 
San Jose, CA) to the whole image. Double immunofluorescence images 
were obtained by superimposing two  single-color pictures of the same 
field.
BrdU incorporation in vitro and in vivo. To assess cell cycle reactivation, 
quiescent cell cultures were cultured for 24 hours in the presence of 20 
μmol/l BrdU (Sigma). Mice were administered 2.6 mmol/l BrdU in drink-
ing water. This route, compared to the more commonly used intraperi-
toneal administration, has the advantage of sparing the animals repeated 
injections and of being more suitable for long-term labeling. Since the 
in vivo half-life of BrdU is less than 1 hour, oral delivery provides more 
uniform labeling over extended periods of time. We observed no side 
effects in mice given BrdU in water for up to 15 days.
RNA extraction, reverse transcription, and real-time PCR quantifica-
tion. Total RNA was extracted from freshly frozen TA muscles with TRIzol 
Reagent (Life Technologies) according to the manufacturer’s instruc-
tions. After treatment with DNase I (New England BioLabs, Ipswich, 
MA), RNA quality was verified by gel electrophoresis. cDNA was synthe-
sized from RNA using the High-Capacity cDNA Reverse Transcription 
Kit (Life Technologies). TaqMan PCR was performed using a 7500 Fast 
Real-Time PCR Systems (Applied Biosystems, Waltham, MA). Amplified 
cDNA (60 ng) was mixed with the SensiMix II Probe reagent (Bioline, 
London, UK), 1 μl of p21 TaqMan Assay (Mouse p21 Mm 01303209_m1 
FAM/MGB probe) and 1 μl of GAPDH TaqMan Assay (Mouse GAPDH 
Endogenous Control VIC/MGB probe (Life Technologies). Amplification 
cycles included 95 °C, 15 seconds denaturing and 60 °C, 60 seconds 
annealing/synthesis steps.
Cell cultures and RNAi experiments. Low-passage human primary foreskin 
fibroblasts (FB1329) were cultured in Dulbecco’s modified Eagle’s medium 
supplemented with 10% FBS (Life Technologies) and antibiotics (100 U/
ml penicillin and 100 µg/ml streptomycin, Life Technologies). Quiescence 
was induced by switching confluent cultures to 0.1% FBS for 48–96 hours, 
depending on the experiment. Cells were considered quiescent when BrdU 
incorporation over 24 hours was lower than 5%. Primary myoblasts were 
isolated and cultured as previously described.32 SKMC human skeletal myo-
blasts from a single donor were obtained from Cambrex (Rutherford, NJ).
siRNA experiments were performed following a previously described 
procedure.6 Briefly, Target cells were transfected with the HiPerFect 
transfection reagent (Qiagen, Venlo, The Netherlands) complexed with 
siRNAs to p21 or control siRNA (siGENOME SMARTpool Upgrades, 
Dharmacon, Lafayette, CO).
Western blot analyses. Proteins were separated on gradient, 4–12% poly-
acrylamide gels (Invitrogen, Carlsbad, CA) and analyzed by western blot-
ting with the following antibodies: β-tubulin (T5293, Sigma); p21 (sc-397, 
Santa Cruz Biotechnology); γ-H2AX (05636, Upstate, Charlottesville, VA). 
Peroxidase-conjugated antisera to mouse and rabbit immunoglobulins were 
purchased from Bio-Rad Laboratories (Hercules, CA). Western blots were 
developed using the LiteAblot Extended substrate (Euroclone, Pero, Italy).
Functional measurements. For functional studies, virus injections were 
performed into TA muscles but, as demonstrated by β-galactosidase stain-
ing and Pax7+ cell enumeration (data not shown), EDL muscles were 
equally infected. EDL muscles were subjected to functional measure-
ments 20 and 60 days after AAV9-p21 or -Ctr infection. Time to peak, half 
relaxation time, maximum force value, and resistance to isotonic fatigue 
were measured as previously described.33 In particular, time to fatigue 
was computed as the time each muscle was able to shorten repeatedly 
against a resistant load equal to one-third of its maximum force. Muscle 
length and weight were measured at the end of each experiment for force 
normalization.
Molecular Therapy vol. 23 no. 5 may 2015 893
© The American Society of Gene & Cell Therapy
p21 Suppression Triggers Proliferation In Vivo
Single cell gel electrophoresis (comet assay). Alkaline single cell 
gel   electrophoresis was performed as described (ref. 34). Briefly, cell sus-
pensions were mixed with 0.5% low melting point  agarose/phosphate-buff-
ered saline (Bio-Rad) and applied to glass microscope slides coated with 
1% low melting point agarose. The gel was allowed to solidify at 4 °C, then 
the slides were submerged in lysis solution (2.5 mol/l NaCl, 100 mmol/l 
 ethylenediaminetetraacetic acid (EDTA), 10 mmol/l Tris, 1% Triton X-100, 
10% dimethyl sulfoxide (DMSO), pH 10) and kept at 4 °C overnight. The 
slides were then incubated for 20 minutes in alkaline buffer (300 mmol/l 
NaOH, 1 mmol/l EDTA, pH 13). Electrophoresis was performed in alkaline 
buffer at 300 mA for 30 minutes at room temperature. After electropho-
resis, the slides were placed in neutralization buffer (0.4 mol/l Tris-NaOH, 
pH 7.5) for 5 minutes and then fixed in cold 100% ethanol for 5 minutes. 
Slides were air dried and stained with ethidium bromide, 20 µg/ml in 
water. Comet images were analyzed using the IAS 2000 7.0 software (Delta 
Sistemi, Roma, Italy). At least 50 nuclei per experimental point were ana-
lyzed. The tail moment parameter is calculated as (percentage of DNA in 
the tail) × (head-to-tail distance). Nuclei with apoptotic morphology (very 
small comet heads and extremely large tails) were excluded from analysis.
Cytogenetic analyses. Subconfluent cultures of FB1329 fibroblasts were 
made quiescent in 0.1% FBS-containing medium and, 48 hours later, trans-
fected with p21 siRNA or fed 10% FBS. After 32 hours (p21 siRNA) or 23 
hours (10% FBS), the cells were processed for metaphase preparation. For 
long-term treatments, quiescent FB1329 fibroblasts were transfected with 
p21 siRNA, maintained in culture in medium containing 0.1% FBS, and 
processed 9 days later for metaphase preparation. Twenty-four hours before 
metaphase preparation, cells transfected with control siRNA were fed 10% 
FBS to induce cell cycle reactivation. To prepare metaphase spreads, the cells 
were treated with 0.4 µg/ml Colcemid (Sigma) for 3 hours at 37 °C, then 
harvested and incubated with 75 mmol/l KCl for 30 minutes at 37 °C. Nuclei 
were fixed in suspension with methanol/acetic acid 3/1 and kept at 4 °C for 
12 hours.35 Chromosome preparations were Giemsa stained; ploidy and 
chromosomal aberrations were scored by direct microscopic examination. 
One hundred metaphase spreads per sample were analyzed.
HPRT gene mutation assay. The HPRT assay was applied to proliferating 
human primary fibroblasts and quiescent ones treated with siRNA to p21 
or control siRNA. At the end of the expression period, 7 × 104 cells were 
seeded into 90-mm dishes in medium containing 10% FBS and 7.5 µg/
ml 6-TG (Sigma). The medium was renewed after 10 days and, after 10 
additional days, colonies of 6-TG-resistant cells were fixed with methanol, 
stained with 5% Giemsa reagent and counted. As a positive control, qui-
escent fibroblasts were treated with 8 joule/m2, 254 nm UV light. Cloning 
efficiency was determined in medium without 6-TG, in parallel, duplicate 
cultures seeded at 100 cells per 60-mm dish and allowed to grow for 10 
days. Colonies were then fixed, stained, and counted as above. Mutation 
frequency is expressed as the number of 6-TG-resistant colonies per 106 
cells, normalized to cloning efficiency.36
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